Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP∼T vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy
| Autor: | K. Maertens, M.R.P. Orije, C. Huoi, F. Boisnard, O. Lyabis |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Whooping Cough
Immunization Secondary Corynebacterium Pregnancy Humans Hepatitis B Vaccines Vaccines Combined Prospective Studies Hepatitis B Antibodies Diphtheria-Tetanus-Pertussis Vaccine Haemophilus Vaccines Tetanus General Veterinary General Immunology and Microbiology Vaccination Infant Newborn Public Health Environmental and Occupational Health Infant Diphtheria Antibodies Bacterial Poliovirus Vaccine Inactivated Infectious Diseases Molecular Medicine Female Human medicine Infant Premature Poliomyelitis |
| Zdroj: | Vaccine |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2022.12.021 |
| Popis: | Background: Vaccination during pregnancy with tetanus, diphtheria, acellular pertussis (aP) (Tdap) anti-gens is important for early protection of newborn infants against pertussis, particularly for preterm infants. This study evaluated the effect of Tdap vaccination during pregnancy on the immunogenicity of a diphtheria (D), tetanus (T), aP, inactivated poliovirus (IPV), hepatitis B (HB), and Haemophilus influen-zae type b (PRP ti T) vaccine in term and preterm populations.Methods: A prospective, observational study (NCT02511327) recruited women and their infants based on delivery (term or preterm) and vaccination status (vaccinated with a Tdap vaccine [BoostrixTM, GlaxoSmithKline] during pregnancy or not vaccinated in the last 5 years). All infants received licensed DTaP-IPV-HB-PRP ti T (HexyonTM, Sanofi) (8, 12, 16 week primary series and booster at 13 months of age [preterm infants] or 15 months of age [term infants]). Immunogenicity was evaluated using validated assays. Data were pooled into term (N = 127) and preterm infants (N = 105), and infants of women who received a Tdap vaccine during pregnancy (N = 199) or not (N = 33).Results: Before primary vaccination, antibody levels were higher for term than preterm infants for anti-D, anti-polio 1, 2, 3, anti-PT, anti-FHA, and anti-PRP, and similar for anti-HBs and anti-T. At this time, infants of Tdap-vaccinated women had higher anti-D, anti-T, anti-PT, anti-FHA, and anti-PRP antibody levels than infants of Tdap-unvaccinated women; anti-HBs and anti-polio antibody levels were similar in both groups. Post-primary, pre-booster, and post-booster, there were only small differences in seroprotection rates (anti-D, anti-T, anti-polio 1, 2, 3, anti-HBs, anti-PRP) and seroconversion rates (anti-PT, anti-FHA), except for anti-HBs >= 10 mIU/mL and anti-PRP >= 0.15 lg/mL post-primary vaccination (higher for term [98.31 % and 90.91 %, respectively] versus preterm infants [89.80 % and 79.41 %, respectively]).Conclusions: These data support the use of DTaP-IPV-HB-PRP ti T vaccine for primary and booster vacci-nation in term and preterm born infants and in infants born to Tdap-vaccinated or Tdap-unvaccinated women.(c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect